DL-3-n-butylphthalide delays the onset and progression of diabetic cataract by inhibiting oxidative stress in rat diabetic model

• DOI: 10.1038/srep19396
• Publication Date: 2016-01-13T12:07:48Z
• Authors: Fuxu Wang; Jia Ma; Fei Han; Xiujin Guo; Li Meng; Yufeng Sun; Cheng Jin; Huijun Duan; Hang Li; Ying Peng
• Keywords: Malondialdehyde; Thiobarbituric acid

Abstract DL-3-n-butylphthalide (NBP) is a therapeutic drug used for ischemic stroke treatment. Here, we investigated the impact of NBP on development rat diabetic cataract induced by intraperitoneal injection streptozotocin (STZ). was then administrated oral gavage nine weeks. Cataract monitored through ophthalmoscope inspections. The levels blood glucose and serum reactive oxygen species (ROS), malondialdehyde (MDA) 8-Hydroxydeovexyguanosine (8-OHdG) were measured. Total soluble protein oxidative stress parameters, such as 2, 4- dinitrophenylhydrazone (DNP), 4-hydroxynonenal (4-HNE) MDA in lenses determined Western blot thiobarbituric acid analyses. expressions NF-E2-related factor 2 (Nrf2) its downstream antioxidant enzymes, thioredoxin (TRX), Catalase nuclear accumulation Nrf2 immunohistochemistry We showed that treatment significantly improved scores, DNP, 4-HNE lens compared to non-treated groups. also enhanced Nrf2, TRX catalase rats. In addition, decreased glucose, 8-OHdG. These results suggested delayed onset progression inhibiting stresses.